FDA Approves Ivosidenib as First-Line Therapy for AML

The FDA approved ivosidenib (Tibsovo, Agios Pharmaceuticals) for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are 75 years of age and older or who have comorbidities that preclude the use of intensive induction chemotherapy.